Cancer Cell Biology

You have full text access to this OnlineOpen article

Toll-like receptors on B-CLL cells: expression and functional consequences of their stimulation

  1. Daniela Rožková1,†,*,
  2. Linda Novotná1,
  3. Robert Pytlík2,
  4. Ivana Hochová3,
  5. Tomáš Kozák4,
  6. Jiřina Bartůňková1,
  7. Radek Špíšek1

Article first published online: 14 AUG 2009

DOI: 10.1002/ijc.24832

Issue

International Journal of Cancer

International Journal of Cancer

Volume 126, Issue 5, pages 1132–1143, 1 March 2010

Additional Information

How to Cite

Rožková, D., Novotná, L., Pytlík, R., Hochová, I., Kozák, T., Bartůňková, J. and Špíšek, R. (2010), Toll-like receptors on B-CLL cells: expression and functional consequences of their stimulation. Int. J. Cancer, 126: 1132–1143. doi: 10.1002/ijc.24832

Author Information

  1. 1

    Institute of Immunology, Charles University, 2nd Faculty of Medicine, University Hospital Motol, Prague, Czech Republic

  2. 2

    First Department of Medicine, Charles University, 1st Faculty of Medicine, General University Hospital, Prague, Czech Republic

  3. 3

    Department of Hematology, Charles University, 2nd Faculty of Medicine, University Hospital Motol, Prague, Czech Republic

  4. 4

    Department of Clinical Hematology, Charles University, 3rd Faculty of Medicine, University Hospital Královské Vinohrady, Prague, Czech Republic

  1. †

    Fax: +420-2-24-43-59-62

*Department of Immunology, 2nd Medical School, Charles University, V Úvalu 84, Prague 5 - Motol, 15006, Czech Republic

Publication History

  1. Issue published online: 27 DEC 2009
  2. Article first published online: 14 AUG 2009
  3. Accepted manuscript online: 14 AUG 2009 12:00AM EST
  4. Manuscript Accepted: 6 AUG 2009
  5. Manuscript Received: 8 JUN 2009

Funded by

  • Grant Agency of Czech Republic. Grant Number: 310/08/P353
  • Ministry of Education. Grant Number: MSM 0021620812

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (979K)

References

  • 1
    Abbott BL. Chronic lymphocytic leukemia: recent advances in diagnosis and treatment. Oncologist 2006; 11: 21–30.
  • 2
    Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005; 352: 804–15.
  • 3
    Hamblin TJ. Prognostic markers in chronic lymphocytic leukaemia. Best Pract Res Clin Haematol 2007; 20: 455–68.
  • 4
    Akira S. Mammalian Toll-like receptors. Curr Opin Immunol 2003; 15: 5–11.
  • 5
    Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4: 499–511.
  • 6
    Cascalho M, Platt JL. Novel functions of B cells. Crit Rev Immunol 2007; 27: 141–51.
  • 7
    Lee JR, Koretzky GA. Production of reactive oxygen intermediates following CD40 ligation correlates with c-Jun N-terminal kinase activation and IL-6 secretion in murine B lymphocytes. Eur J Immunol 1998; 28: 4188–97.
  • 8
    Yi AK, Klinman DM, Martin TL, Matson S, Krieg AM. Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of. IL-6 transcription through an antioxidant-sensitive pathway. J Immunol 1996; 157: 5394–402.
  • 9
    Hayashi EA, Akira S, Nobrega A. Role of TLR in B cell development: signaling through TLR4 promotes B cell maturation and is inhibited by TLR2. J Immunol 2005; 174: 6639–47.
  • 10
    Ruprecht CR, Lanzavecchia A. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol 2006; 36: 810–16.
  • 11
    Bernasconi NL, Onai N, Lanzavecchia A. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood 2003; 101: 4500–4.
  • 12
    Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002; 298: 2199–202.
  • 13
    Borsutzky S, Kretschmer K, Becker PD, Muhlradt PF, Kirschning CJ, Weiss S, Guzman CA. The mucosal adjuvant macrophage-activating lipopeptide-2 directly stimulates B lymphocytes via the TLR2 without the need of accessory cells. J Immunol 2005; 174: 6308–13.
  • 14
    Mansson A, Adner M, Hockerfelt U, Cardell LO. A distinct Toll-like receptor repertoire in human tonsillar B cells, directly activated by PamCSK, R-837 and CpG-2006 stimulation. Immunology 2006; 118: 539–48.
  • 15
    Grandjenette C, Kennel A, Faure GC, Bene MC, Feugier P. Expression of functional toll-like receptors by B-chronic lymphocytic leukemia cells. Haematologica 2007; 92: 1279–81.
  • 16
    Spaner DE, Shi Y, White D, Mena J, Hammond C, Tomic J, He L, Tomai MA, Miller RL, Booth J, Radvanyi L. Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells. Leukemia 2006; 20: 286–95.
  • 17
    Tomic J, White D, Shi Y, Mena J, Hammond C, He L, Miller RL, Spaner DE. Sensitization of IL-2 signaling through TLR-7 enhances B lymphoma cell immunogenicity. J Immunol 2006; 176: 3830–9.
  • 18
    Spaner DE, Masellis A. Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia. Leukemia 2007; 21: 53–60.
  • 19
    Jahrsdorfer B, Blackwell SE, Wooldridge JE, Huang J, Andreski MW, Jacobus LS, Taylor CM, Weiner GJ. B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation. Blood 2006; 108: 2712–19.
  • 20
    Jahrsdorfer B, Wooldridge JE, Blackwell SE, Taylor CM, Griffith TS, Link BK, Weiner GJ. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. J Leukoc Biol 2005; 77: 378–87.
  • 21
    Sochorova K, Horvath R, Rozkova D, Litzman J, Bartunkova J, Sediva A, Spisek R. Impaired Toll-like receptor 8-mediated IL-6 and TNF-alpha production in antigen-presenting cells from patients with X-linked agammaglobulinemia. Blood 2007; 109: 2553–6.
  • 22
    Jarrossay D, Napolitani G, Colonna M, Sallusto F, Lanzavecchia A. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol 2001; 31: 3388–93.
  • 23
    Ibrahim S, Keating M, Do KA, O'Brien S, Huh YO, Jilani I, Lerner S, Kantarjian HM, Albitar M. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 2001; 98: 181–6.
  • 24
    Caligaris-Cappio F, Ghia P. The normal counterpart to the chronic lymphocytic leukemia B cell. Best Pract Res Clin Haematol 2007; 20: 385–97.
  • 25
    Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, Husson H, Freedman A, Inghirami G, Cro L, Baldini L, Neri A, Califano A, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001; 194: 1625–38.
  • 26
    Klein U, Dalla-Favera R. New insights into the phenotype and cell derivation of B cell chronic lymphocytic leukemia. Curr Top Microbiol Immunol 2005; 294: 31–49.
  • 27
    Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, Buchbinder A, Budman D, Dittmar K, Kolitz J, Lichtman SM, Schulman P, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840–7.
  • 28
    Chiorazzi N, Ferrarini M. B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol 2003; 21: 841–94.
  • 29
    Krieg AM. CpG motifs: the active ingredient in bacterial extracts? Nat Med 2003; 9: 831–5.
  • 30
    Muzio M, Scielzo C, Bertilaccio MT, Frenquelli M, Ghia P, Caligaris-Cappio F. Expression and function of toll like receptors in chronic lymphocytic leukaemia cells. Br J Haematol 2009; 144: 507–16.
  • 31
    Girardin SE, Travassos LH, Herve M, Blanot D, Boneca IG, Philpott DJ, Sansonetti PJ, Mengin-Lecreulx D. Peptidoglycan molecular requirements allowing detection by Nod1 and Nod2. J Biol Chem 2003; 278: 41702–8.
  • 32
    Schroder NW, Morath S, Alexander C, Hamann L, Hartung T, Zahringer U, Gobel UB, Weber JR, Schumann RR. Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved. J Biol Chem 2003; 278: 15587–94.
  • 33
    Yu Z, Sun B, Kantarjian HM, Keating MJ, Amin HM, Sun X. Protein expression profiling of cytokines and cytokine receptors on purified chronic lymphocytic leukemia cells from patients with favourable prognostic indicators. Leuk Lymphoma 2008; 49: 751–6.
  • 34
    Aderka D, Maor Y, Novick D, Engelmann H, Kahn Y, Levo Y, Wallach D, Revel M. Interleukin-6 inhibits the proliferation of B-chronic lymphocytic leukemia cells that is induced by tumor necrosis factor-alpha or -beta. Blood 1993; 81: 2076–84.
  • 35
    Reittie JE, Yong KL, Panayiotidis P, Hoffbrand AV. Interleukin-6 inhibits apoptosis and tumour necrosis factor induced proliferation of B-chronic lymphocytic leukaemia. Leuk Lymphoma 1996; 22: 83–90.
  • 36
    Fayad L, Keating MJ, Reuben JM, O'Brien S, Lee BN, Lerner S, Kurzrock R. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood 2001; 97: 256–63.
  • 37
    Lai R, O'Brien S, Maushouri T, Rogers A, Kantarjian H, Keating M, Albitar M. Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia. Cancer 2002; 95: 1071–5.
  • 38
    Chiron D, Bekeredjian-Ding I, Pellat-Deceunynck C, Bataille R, Jego G. Toll-like receptors: lessons to learn from normal and malignant human B cells. Blood 2008; 112: 2205–13.
  • 39
    Romano C, De Fanis U, Sellitto A, Chiurazzi F, Guastafierro S, Giunta R, Tirelli A, Rotoli B, Lucivero G. Induction of CD95 upregulation does not render chronic lymphocytic leukemia B-cells susceptible to CD95-mediated apoptosis. Immunol Lett 2005; 97: 131–9.
  • 40
    Morabito F, Damle RN, Deaglio S, Keating M, Ferrarini M, Chiorazzi N. The CD38 ectoenzyme family: advances in basic science and clinical practice. Mol Med 2006; 12: 342–4.
  • 41
    Giordani L, Sanchez M, Libri I, Quaranta MG, Mattioli B, Viora M. IFN-{alpha} amplifies human naive B cell TLR-9-mediated activation and Ig production. J Leukoc Biol 2009; 86: 261–71.
  • 42
    Pittner BT, Shanafelt TD, Kay NE, Jelinek DF. CD38 expression levels in chronic lymphocytic leukemia B cells are associated with activation marker expression and differential responses to interferon stimulation. Leukemia 2005; 19: 2264–72.
  • 43
    Chang CC, Cleveland RP. Conversion of CD38 and/or myeloid-associated marker expression status during the course of B-CLL: association with a change to an aggressive clinical course. Blood 2002; 100: 1106.
  • 44
    Hamblin TJ, Orchard JA, Ibbotson RE, Davis Z, Thomas PW, Stevenson FK, Oscier DG. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002; 99: 1023–9.
  • 45
    Deaglio S, Vaisitti T, Bergui L, Bonello L, Horenstein AL, Tamagnone L, Boumsell L, Malavasi F. CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival. Blood 2005; 105: 3042–50.
View Full Article (HTML) Get PDF (979K)